By Elie Dolgin

Between the recently approved prophylactic vaccines against the human papillomavirus (HPV), and the ease with which surgery can treat most cervical cancers, therapeutic treatments for the virus have been low on most clinicians’ priority lists. But with increasing incidence of other HPV-associated cancers that are more difficult to treat surgically—for example, oral cancer—a new generation of therapies aimed at HPV-induced precancerous lesions and warts could be on the horizon. (Click here to continue reading)

Image by euthman via Flickr Creative Commons